Europe Kidney Cancer Diagnostics Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2023 –2030 |
 حجم السوق (السنة الأساسية) |
|
 حجم السوق (سنة التنبؤ) |
USD 3,572.63 |
 CAGR |
% |
| Major Markets Players |
سوق تشخيص سرطان الكلى في أوروبا، حسب نوع الاختبار (التصوير، اختبار المؤشرات الحيوية، اختبار الدم، الخزعة، الاختبار الجيني، وغيرها)، مرحلة السرطان (المرحلة الأولى، المرحلة الثانية، المرحلة الثالثة، والمرحلة الرابعة)، نوع الورم (سرطان الخلايا الكلوية، سرطان الخلايا الكلوية الصافية، سرطان الخلايا الكلوية غير الصافية)، المنتج (المنتجات القائمة على المنصة، المنتجات القائمة على الأدوات، المجموعات والكواشف، والمواد الاستهلاكية الأخرى)، التكنولوجيا ( التهجين الموضعي الفلوري ، التسلسل الجيني للجيل التالي، المقايسة المناعية الفلورية، التهجين الجينومي المقارن، المناعة الكيميائية، وغيرها)، التطبيق (الفحص والتشخيص والتنبؤ والتنبؤ والبحث)، المستخدم النهائي (المستشفيات ومراكز التشخيص ومراكز أبحاث السرطان والمعاهد الأكاديمية ومراكز الجراحة الخارجية وغيرها)، قناة التوزيع (العطاء المباشر ومبيعات التجزئة وغيرها)، اتجاهات الصناعة والتوقعات 2030.
تحليل وحجم سوق تشخيص سرطان الكلى في أوروبا
يبدأ سرطان الكلى عندما تتغير الخلايا السليمة في إحدى الكليتين أو كلتيهما وتنمو بشكل لا يمكن السيطرة عليه، مكونة كتلة تسمى الورم القشري. يمكن أن يكون الورم خبيثًا أو خاملًا أو حميدًا. الورم الخبيث هو السرطان، مما يعني أنه يمكن أن ينمو وينتشر إلى أجزاء أخرى من الجسم. الورم الخامل هو أيضًا سرطان، لكن هذا النوع من الأورام نادرًا ما ينتشر إلى أجزاء أخرى من الجسم. الورم الحميد يعني أن الورم يمكن أن ينمو ولكن لا ينتشر.
لقد أدى الوعي المتزايد بسرطان الكلى في أوروبا إلى تعزيز الطلب على السوق. كما يساهم ارتفاع الإنفاق على الرعاية الصحية لتحسين الخدمات الصحية في نمو السوق. يركز اللاعبون الرئيسيون في السوق على إطلاق خدمات مختلفة والموافقات عليها خلال هذه الفترة الحاسمة. بالإضافة إلى ذلك، يساهم زيادة الإجراءات التشخيصية المحسنة لسرطان الكلى أيضًا في زيادة الطلب على اختبارات تشخيص سرطان الكلى.
من المتوقع أن ينمو سوق تشخيص سرطان الكلى في أوروبا في العام المتوقع بسبب زيادة عدد اللاعبين في السوق وتوافر الخدمات المتقدمة. إلى جانب ذلك، يشارك المصنعون في أنشطة البحث والتطوير لإطلاق خدمات جديدة في السوق. ومن المتوقع أن يعزز البحث المتزايد في مجال تشخيص الكلى وتطويرها نمو السوق. ومع ذلك، من المتوقع أن يعيق تلف الأنسجة بسبب التعرض للإشعاع العالي من اختبارات التصوير نمو سوق تشخيص سرطان الكلى في أوروبا في الفترة المتوقعة.
تحلل شركة Data Bridge Market Research أن سوق تشخيص سرطان الكلى من المتوقع أن تصل قيمته إلى 3,572.63 مليون دولار أمريكي بحلول عام 2030، بمعدل نمو سنوي مركب قدره 6.1% خلال الفترة المتوقعة. تشكل التصوير أكبر شريحة من أنواع الاختبارات في السوق بسبب الطلب المتزايد على الأجهزة الذكية، كما أدى زيادة الإنفاق الصحي إلى تسريع الطلب على الأجهزة الطبية الذكية.
|
تقرير القياس |
تفاصيل |
|
فترة التنبؤ |
2023 إلى 2030 |
|
سنة الأساس |
2022 |
|
سنوات تاريخية |
2021 (قابلة للتخصيص حتى 2020-2016) |
|
وحدات كمية |
الإيرادات بالملايين من الدولارات الأمريكية، الأحجام بالوحدات، التسعير بالدولار الأمريكي |
|
القطاعات المغطاة |
حسب نوع الاختبار (التصوير، اختبار المؤشرات الحيوية، اختبار الدم، الخزعة، الاختبار الجيني، وغيرها)، مرحلة السرطان (المرحلة الأولى، المرحلة الثانية، المرحلة الثالثة، والمرحلة الرابعة)، نوع الورم (سرطان الخلايا الكلوية، سرطان الخلايا الكلوية الصافية، سرطان الخلايا الكلوية غير الصافية)، المنتج (المنتجات القائمة على المنصة، المنتجات القائمة على الأدوات، مجموعات وكواشف، وغيرها من المواد الاستهلاكية)، التكنولوجيا (التهجين الموضعي الفلوري، تسلسل الجيل التالي، المقايسة المناعية الفلورية، التهجين الجينومي المقارن، المناعة الكيميائية، وغيرها)، التطبيق (الفحص والتشخيص والتنبؤ والتنبؤ والبحث)، المستخدم النهائي (المستشفيات ومراكز التشخيص ومراكز أبحاث السرطان والمعاهد الأكاديمية ومراكز الجراحة الخارجية وغيرها)، قناة التوزيع (العطاء المباشر، مبيعات التجزئة وغيرها). |
|
الدول المغطاة |
ألمانيا، فرنسا، المملكة المتحدة، إيطاليا، روسيا، إسبانيا، هولندا، سويسرا، النرويج، بولندا، السويد، بلجيكا، تركيا، الدنمارك، فنلندا وبقية أوروبا. |
|
الجهات الفاعلة في السوق المشمولة |
Siemens Healthcare GmbH، Koninklijke Philips NV، FUJIFILM Corporation، Grail، Laboratory Corporation of America Holdings، Thermo Fisher Scientific، Myriad Genetics, Inc.، CANON MEDICAL SYSTEMS CORPORATION، QIAGEN، Illumina Inc.، Ambry Genetics، Invitae Corporation، General Electric Company، Centogene NV، GenPath، Creative Diagnostics، GeneDx LLC، Blueprint Genetics Oy، BioVendor R&D، وCD Genomics، وBD، من بين شركات أخرى |
تعريف السوق
سرطان الكلى، المعروف باسم سرطان الكلى، هو حالة تتطور فيها خلايا الكلى إلى أورام خبيثة (سرطانية) وتتوسع بشكل لا يمكن السيطرة عليه. يعد سرطان الكلى أحد أكثر 10 أنواع من السرطان انتشارًا. سرطان الكلى مميت، كما أن عملية التشخيص بها أيضًا مشكلات تتعلق بالسلامة؛ فهي ليست فعالة من حيث التكلفة. قد يتم إدخال مرضى السرطان إلى المستشفى وتلقي مجموعة متنوعة من العلاجات، مثل الجراحة والعلاج الإشعاعي والعلاج الجهازي. حوالي 40٪ من نمو الكلى عبارة عن كتل صغيرة وموضعية. يشير الموضعي إلى الورم الذي لم ينتشر من موقعه الأصلي. لا يمكن اكتشاف كتل الكلى بالإجراءات المعملية العادية. يشمل تشخيص سرطان الكلى إجراءات الخزعة وفحوصات الدم واختبارات التصوير. ينصح بالعلاجات المتقدمة لسرطان الكلى، مثل العلاج المناعي والعلاج الإشعاعي وما إلى ذلك. نظرًا للطرق المتطورة، تُستخدم أحيانًا إجراءات غير جراحية مثل التجميد بالتبريد (الذي يجمد خلايا السرطان) والاستئصال بالترددات الراديوية لعلاج أورام الكلى البسيطة (خلايا السرطان الحرارية).
قد يكون تشخيص سرطان الكلى صعبًا، وذلك لأنه على الرغم من تنوع علاماته وأعراضه، إلا أنها غير محددة ويمكن ربطها بحالات طبية أخرى أكثر انتشارًا. يتم تشخيص أكثر من 43000 رجل و25000 امرأة بسرطان الكلى وحوض الكلى كل عام، ويموت 9000 رجل و5000 امرأة نتيجة لهذا المرض. ومع ذلك، من المتوقع أن تعمل اللوائح والمعايير الصارمة للموافقة على منتجات تشخيص سرطان الكلى وتسويقها على كبح نمو السوق.
ديناميكيات سوق تشخيص سرطان الكلى في أوروبا
يتناول هذا القسم فهم محركات السوق والمزايا والفرص والقيود والتحديات. وسيتم مناقشة كل هذا بالتفصيل أدناه:
السائقين
- تزايد انتشار سرطان الكلى
يمكن أن تتأثر جميع الأعمار بهذا النوع من السرطان. قد يكون تشخيص سرطان الكلى صعبًا لأنه على الرغم من نطاقه الواسع من العلامات والأعراض، إلا أنها غير محددة ويمكن ربطها بحالات طبية أخرى أكثر انتشارًا. عادةً لا تظهر علامات أو أعراض لسرطان الكلى في مراحله المبكرة. بمرور الوقت، قد تظهر علامات وأعراض، بما في ذلك الدم في البول، والذي قد يبدو ورديًا أو أحمر أو بلون الكولا، وألم في الظهر أو الجانب لا يزول، وفقدان الشهية، وفقدان الوزن غير المبرر، والتعب، والحمى. في البالغين، يعد سرطان الكلى النوع الأكثر شيوعًا من السرطان. الأطفال الصغار أكثر عرضة للإصابة بنوع من سرطان الكلى يسمى ورم ويلمز. سرطان الكلى (المعروف أيضًا بسرطان الكلى أو سرطان الخلايا الكلوية الغدي) هو السرطان الرابع عشر الأكثر شيوعًا في جميع أنحاء العالم. وهو التاسع بين الرجال والرابع عشر بين النساء. في عام 2020، تم تشخيص أكثر من 30000 حالة جديدة من سرطان الكلى.
بسبب عوامل الخطر المختلفة مثل التدخين والسمنة وارتفاع ضغط الدم أو التاريخ العائلي للإصابة بسرطان الكلى، فإن عدد مرضى سرطان الكلى في تزايد في أوروبا وأصبح قضية اجتماعية واقتصادية مهمة. وبالتالي فإن العدد المتزايد من مرضى سرطان الكلى يزيد من الطلب على منتجات تشخيص سرطان الكلى التي تعمل كمحرك في سوق تشخيص سرطان الكلى في أوروبا.
- زيادة في إجراءات التشخيص لسرطان الكلى
تشمل التقنيات المستخدمة لتشخيص سرطان الكلى الموجات فوق الصوتية، والتصوير المقطعي المحوسب، والتصوير بالرنين المغناطيسي، وفي بعض الأحيان التصوير المقطعي بالإصدار البوزيتروني. قد يتضمن علاج سرطان الكلى الذي ينمو بمعدل بطيء المراقبة. في بعض الأحيان يتم الجمع بين العلاج الكيميائي للأورام الخبيثة والعلاج الإشعاعي وزرع الخلايا الجذعية. كانت معدلات الإصابة بالسرطان المتزايدة عاملاً معززًا لزيادة الموافقة على المنتجات التشخيصية.
وبالتالي، أدى ارتفاع الموافقات على المنتجات التشخيصية إلى زيادة عدد المنتجات عالية الكفاءة في السوق لعلاج سرطان الكلى. ومن المتوقع أن يعمل هذا كمحرك لنمو سوق تشخيص سرطان الكلى في أوروبا.
فرصة
-
تزايد الإقبال على إجراء الفحوصات الصحية الوقائية
الفحص الصحي الوقائي هو إجراءات وقائية يتم إجراؤها للكشف الأولي عن مرض سرطان الكلى. كما أن التفضيل المتزايد للفحوصات الصحية الوقائية يوفر حماية ضد التعرض المحتمل لأي مرض في المستقبل.
إن التوعية لتعزيز الفحص هو أهم عنصر للوقاية من سرطان الكلى. ويتألف الفحص من تحديد السرطان وفحص عوامل الخطر للحد من الخسارة في مرحلة مبكرة.
يتم إجراء الفحص الوقائي لسرطان الكلى بمساعدة اختبارات تشخيصية مختلفة، بما في ذلك الخزعة، والمناعة الكيميائية، وفحص السرطان، والتصوير بالرنين المغناطيسي وغيرها.
إن الناس أكثر عرضة نسبيًا لأمراض سرطان الكلى. لذلك، فهم يحتاجون إلى إجراء فحوصات منتظمة لتسهيل فهم الأطباء للأمراض وتوفير علاج أفضل للمريض الذي يعاني من السرطان، ولهذا السبب من المتوقع أن يعمل التفضيل المتزايد للفحوصات الصحية الوقائية كمحرك لنمو سوق تشخيص سرطان الكلى في أوروبا.
ضبط النفس/التحدي
- قواعد ومعايير صارمة للموافقة على منتجات تشخيص سرطان الكلى وتسويقها
لقد ثبت أن اللوائح الصارمة لتسويق أي منتج في السوق تشكل تحديًا كبيرًا لمصنعي منتجات تشخيص السرطان في أوروبا التي لديها لوائح وهيئة مختلفة للإجراءات التنظيمية.
يتعين على الشركات المصنعة أولاً التحقق من موافقة علامة CE لتسويق منتجاتها في السوق الأوروبية. ومن المتوقع أن تعيق السياسات التنظيمية الصارمة تطوير سوق تشخيص السرطان. وقد يؤدي المتطلب التنظيمي للحصول على موافقات التسويق أو شهادة CE وتطبيق القوانين واللوائح إلى تغييرات تجارية كبيرة أو دفع غرامات، بما في ذلك الخسارة المحتملة لرخص العمل. والموارد والتكاليف المطلوبة للامتثال لهذه القوانين والقواعد واللوائح مرتفعة.
قد يختلف المتطلب التنظيمي للحصول على الموافقات التسويقية وإعلان المطابقة والوقت المطلوب للمراجعة التنظيمية باختلاف المنتجات. الشركة التي تفشل في الحصول على الموافقة التنظيمية تضر بالعمل لأنه بدون الحصول على الموافقة أو الفشل في الحصول على علامة CE للموافقة على المنتجات، لا يتمكن المصنعون من إطلاق منتجاتهم في السوق الأوروبية، ولهذا السبب، من المتوقع أن تعمل اللوائح والمعايير الصارمة للموافقة على منتجات تشخيص سرطان الكلى وتسويقها كقيد لسوق تشخيص سرطان الكلى في أوروبا.
التطورات الأخيرة
- في نوفمبر 2022، أعلنت شركة Koninklijke Philips NV عن إطلاق الجيل القادم من حلول الموجات فوق الصوتية المحمولة المدمجة في أوروبا في الاجتماع السنوي للجمعية الإشعاعية لأمريكا الشمالية (RSNA) لجلب جودة التشخيص المرتبطة بأنظمة الموجات فوق الصوتية المتميزة القائمة على العربات إلى المزيد من المرضى. إنه محمول ومتعدد الاستخدامات مع جودة صورة أو أداء جيد. وهو متوافق مع أنظمة الموجات فوق الصوتية من Philips Affiniti ومحول EPIQ. وقد ساعد هذا الشركة على توسيع مجموعة منتجاتها.
- في أكتوبر 2022، تعاونت شركة جنرال إلكتريك مع العديد من معاهد الأبحاث مثل مستشفيات جامعة كامبريدج، وSophia Genetics، وفي وقت سابق مع Optellum لاستخدام بيانات التصوير بالتعاون مع الذكاء الاصطناعي. سيساعد هذا في تقليل وقت تشخيص العديد من أنواع السرطان والمساعدة في تقديم رعاية شخصية للمرضى. وقد ساعد هذا الشركة على توسيع آفاقها في تشخيص السرطان.
- في يوليو 2022، أعلنت شركة Canon Medical Systems USA Inc. عن استكمال عملية الاستحواذ على شركة NXC Imaging، وهي شركة توزيع معدات التصوير الطبي ومزودة الخدمات ومقرها في ولاية مينيسوتا بالولايات المتحدة. ويؤدي هذا إلى توسيع نطاق الخدمة في السوق الأوروبية.
نطاق سوق تشخيص سرطان الكلى في أوروبا
ينقسم سوق تشخيص سرطان الكلى في أوروبا إلى ثمانية قطاعات بارزة بناءً على نوع الاختبار ومرحلة السرطان ونوع الورم والمنتج والتطبيق والتكنولوجيا والمستخدم النهائي وقناة التوزيع. يساعدك النمو بين القطاعات على تحليل جيوب النمو والاستراتيجيات المتخصصة للتعامل مع السوق وتحديد مجالات التطبيق الأساسية والاختلاف في الأسواق المستهدفة.
نوع الاختبار
- اختبار التصوير
- اختبار المؤشرات الحيوية
- فحص الدم
- خزعة
- الاختبار الجيني
- آحرون
على أساس نوع الاختبار، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى التصوير، واختبار المؤشرات الحيوية، واختبار الدم، والخزعة، والاختبارات الجينية، وغيرها.
مرحلة السرطان
- المرحلة الأولى
- المرحلة الثانية
- المرحلة الثالثة
- المرحلة الرابعة
على أساس مرحلة السرطان، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى المرحلة الأولى والمرحلة الثانية والمرحلة الثالثة والمرحلة الرابعة.
نوع الورم
- سرطان الخلايا الكلوية
- سرطان الخلايا الكلوية الصافية
- سرطان الخلايا الكلوية غير الصافية
على أساس نوع الورم، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى سرطان الخلايا الكلوية، وسرطان الخلايا الكلوية الصافية، وسرطان الخلايا الكلوية غير الصافية.
منتج
- المنتجات القائمة على المنصة
- المنتجات القائمة على الأدوات
- أطقم و كواشف
- المواد الاستهلاكية الأخرى
على أساس المنتج، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى منتجات تعتمد على الأدوات، ومنتجات تعتمد على المنصات، ومجموعات وكواشف، ومواد استهلاكية أخرى.
تكنولوجيا
- التهجين الفلوري في الموقع
- تسلسل الجيل القادم
- اختبار الفلوروإيمونواسايز
- التهجين الجينومي المقارن
- مناعي نسيجي
- آحرون
على أساس التكنولوجيا، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى التهجين الموضعي الفلوري، والتسلسل من الجيل التالي، والتحليل المناعي الفلوري، والتهجين الجينومي المقارن، والمناعة الكيميائية النسيجية، وغيرها.
طلب
- الفحص
- التشخيص والتنبؤ
- التنبؤ
- بحث
على أساس التطبيق، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى الفحص والتشخيص والتنبؤ والتنبؤ والبحث.
المستخدم النهائي
- المستشفيات
- مراكز أبحاث السرطان
- المعاهد الأكاديمية
- مراكز التشخيص
- مراكز الجراحة الخارجية
- آحرون
على أساس المستخدمين النهائيين، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى المستشفيات ومراكز التشخيص ومراكز أبحاث السرطان والمعاهد الأكاديمية ومراكز الجراحة الخارجية وغيرها.
قناة التوزيع
- العطاءات المباشرة
- مبيعات التجزئة
- آحرون
على أساس قناة التوزيع، يتم تقسيم سوق تشخيص سرطان الكلى في أوروبا إلى العطاءات المباشرة ومبيعات التجزئة وغيرها.
تحليل/رؤى إقليمية لسوق تشخيص سرطان الكلى في أوروبا
يتم تحليل سوق تشخيص سرطان الكلى في أوروبا وتوفير معلومات حول حجم السوق بناءً على البلد ونوع الاختبار ومرحلة السرطان ونوع الورم والمنتج والتطبيق والتكنولوجيا والمستخدم النهائي وقناة التوزيع.
الدول التي يغطيها تقرير السوق هذا هي ألمانيا وفرنسا والمملكة المتحدة وإيطاليا وروسيا وإسبانيا وهولندا وسويسرا والنرويج وبولندا والسويد وبلجيكا وتركيا والدنمارك وفنلندا وبقية أوروبا.
تهيمن المملكة المتحدة على منطقة أوروبا بسبب الإنتاج الضخم للأجهزة والطلب المتزايد من الأسواق الناشئة وتوسع صناعات الرعاية الصحية.
كما يوفر قسم الدولة في التقرير عوامل فردية مؤثرة على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية الأوروبية والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل تنبؤي لبيانات الدولة.
تحليل المنافسة وحصة سوق تشخيص سرطان الكلى في أوروبا
يوفر المشهد التنافسي لسوق تشخيص سرطان الكلى تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وموافقات المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق، ومنحنى خط الحياة لنوع المنتج. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة على سوق تشخيص سرطان الكلى.
بعض اللاعبين الرئيسيين العاملين في السوق هم Siemens Healthcare GmbH و Koninklijke Philips NV و FUJIFILM Corporation و Grail و Laboratory Corporation of America Holdings و Thermo Fisher Scientific و Myriad Genetics، Inc. و CANON MEDICAL SYSTEMS CORPORATION و QIAGEN و Illumina Inc. و Ambry Genetics و Invitae Corporation و General Electric Company و Centogene NV و GenPath و Creative Diagnostics و GeneDx LLC و Blueprint Genetics Oy و BioVendor R&D و CD Genomics و BD، من بين آخرين.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S 5 FORCES
4.3 EPIDEMIOLOGY
4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES
4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES
5 INDUSTRY INSIGHTS
6 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF KIDNEY CANCER
7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER
7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER
7.2 RESTRAINTS
7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS
7.3 OPPORTUNITIES
7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS
7.4 CHALLENGES
7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS
8 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING
8.2.1 COMPUTED TOMOGRAPHY
8.2.2 ULTRASOUND
8.2.3 MAGNETIC RESONANCE IMAGING (MRI)
8.2.4 ANGIOGRAPHY
8.2.5 X-RAY
8.2.6 OTHERS
8.3 BLOOD TEST
8.4 BIOPSY
8.4.1 FINE NEEDLE ASPIRATION
8.4.2 NEEDLE CORE BIOPSY
8.5 BIOMARKER TEST
8.5.1 AQUAPORIN 1 (AQP1)
8.5.2 PERILIPIN (PLIN2)
8.5.3 N-METHYLTRANSFERASE (NMNT)
8.5.4 L-PLASTIN (LCP-1)
8.5.5 NM23A
8.6 GENETIC TEST
8.7 OTHERS
9 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE
9.1 OVERVIEW
9.2 STAGE I
9.3 STAGE II
9.4 STAGE III
9.5 STAGE IV
10 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE
10.1 OVERVIEW
10.2 RENAL CELL CARCINOMA
10.2.1 IMAGING
10.2.2 BLOOD TEST
10.2.3 BIOPSY
10.2.4 BIOMARKER TEST
10.2.5 GENETIC TEST
10.2.6 OTHERS
10.3 CLEAR CELL RENAL CELL CARCINOMA
10.3.1 IMAGING
10.3.2 BLOOD TEST
10.3.3 BIOPSY
10.3.4 BIOMARKER TEST
10.3.5 GENETIC TEST
10.3.6 OTHERS
10.4 NON CLEAR CELL RENAL CELL CARCINOMA
10.4.1 PAPILLARY RENAL CELL CARCINOMA
10.4.1.1 IMAGING
10.4.1.2 BLOOD TEST
10.4.1.3 BIOPSY
10.4.1.4 BIOMARKER TEST
10.4.1.5 GENETIC TEST
10.4.1.6 OTHERS
10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA
10.4.2.1 IMAGING
10.4.2.2 BLOOD TEST
10.4.2.3 BIOPSY
10.4.2.4 BIOMARKER TEST
10.4.2.5 GENETIC TEST
10.4.2.6 OTHERS
11 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 INSTRUMENT BASED PRODUCTS
11.2.1 IMAGING
11.2.2 BIOPSY
11.3 PLATFORM BASED PRODUCTS
11.3.1 NEXT GENERATION SEQUENCING
11.3.2 MICROARRAYS
11.3.3 PCR
11.3.4 OTHERS
11.4 KITS AND REAGENTS
11.4.1 RENAL CANCER PANELS
11.4.2 RENAL CANCER ANTIBODIES
11.5 OTHER CONSUMABLES
12 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
12.1 OVERVIEW
12.2 FLUORESCENT IN SITU HYBRIDIZATION
12.3 NEXT GENERATION SEQUENCING
12.4 FLUORIMMUNOASSAY
12.5 COMPARATIVE GENOMIC HYBRIDIZATION
12.6 IMMUNOHISTOCHEMICAL
12.7 OTHERS
13 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 SCREENING
13.2.1 INSTRUMENT BASED PRODUCTS
13.2.2 PLATFORM BASED PRODUCTS
13.2.3 KITS AND REAGENTS
13.2.4 OTHER CONSUMABLES
13.3 DIAGNOSTIC AND PREDICTIVE
13.3.1 INSTRUMENT BASED PRODUCTS
13.3.2 PLATFORM BASED PRODUCTS
13.3.3 KITS AND REAGENTS
13.3.4 OTHER CONSUMABLES
13.4 PROGNOSTIC
13.4.1 INSTRUMENT BASED PRODUCTS
13.4.2 PLATFORM BASED PRODUCTS
13.4.3 KITS AND REAGENTS
13.4.4 OTHER CONSUMABLES
13.5 RESEARCH
13.5.1 INSTRUMENT BASED PRODUCTS
13.5.2 PLATFORM BASED PRODUCTS
13.5.3 KITS AND REAGENTS
13.5.4 OTHER CONSUMABLES
14 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 DIAGNOSTIC CENTERS
14.4 CANCER RESEARCH CENTERS
14.5 ACADEMIC INSTITUTES
14.6 AMBULATORY SURGICAL CENTERS
14.7 OTHERS
15 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.4 OTHERS
16 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION
16.1 EUROPE
16.1.1 GERMANY
16.1.2 FRANCE
16.1.3 UNITED KINGDOM
16.1.4 ITALY
16.1.5 SPAIN
16.1.6 RUSSIA
16.1.7 NETHERLANDS
16.1.8 POLAND
16.1.9 SWITZERLAND
16.1.10 BELGIUM
16.1.11 SWEDEN
16.1.12 NORWAY
16.1.13 DENMARK
16.1.14 FINLAND
16.1.15 TURKEY
16.1.16 REST OF EUROPE
17 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: EUROPE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 CANON MEDICAL SYSTEMS CORPORATION
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY PROFILE
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENT
19.2 KONINKLIJKE PHILIPS N.V.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY PROFILE
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 GENERAL ELECTRIC COMPANY
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY PROFILE
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 SIEMENS HEALTHCARE GMBH
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY PROFILE
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENT
19.5 GRAIL
19.5.1 COMPANY SNAPSHOT
19.5.2 PRODUCT PORTFOLIO
19.5.3 RECENT DEVELOPMENTS
19.6 AMBRY GENETICS
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BIOVENDOR R&D
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 BLUEPRINT GENETICS OY.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 CD GENOMICS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CENTOGENE N.V.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 CREATIVE DIAGNOSTICS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 FUJIFILM CORPORATION
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 GENEDX, LLC
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.13.4 RECENT DEVELOPMENT
19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 ILLUMINA, INC.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 INVITAE CORPORATION
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 MYRIAD GENETICS, INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 THERMO FISHER SCIENTIFIC INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENT
19.2 QIAGEN
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
List of Table
TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS
TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER
TABLE 3 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 4 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 5 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 6 EUROPE BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 9 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 14 EUROPE STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 25 EUROPE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 26 EUROPE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 27 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 31 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 32 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 35 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 36 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 39 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 EUROPE OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 42 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 51 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 53 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 55 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 57 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 58 EUROPE HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 EUROPE CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 EUROPE AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 65 EUROPE DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 EUROPE RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 67 EUROPE OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 69 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 71 EUROPE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 72 EUROPE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 73 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 74 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 75 EUROPE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 76 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 77 EUROPE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 78 EUROPE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 79 EUROPE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 80 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 81 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 82 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 83 EUROPE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 84 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 85 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 86 EUROPE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 87 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 88 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 89 EUROPE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 90 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 91 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 92 EUROPE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 EUROPE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 EUROPE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 EUROPE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 96 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 97 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 98 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 GERMANY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 GERMANY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 101 GERMANY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 102 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 103 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 104 GERMANY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 GERMANY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 107 GERMANY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 GERMANY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 109 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 110 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 111 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 112 GERMANY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 113 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 115 GERMANY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 116 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 117 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 118 GERMANY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 119 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 120 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 121 GERMANY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 122 GERMANY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 123 GERMANY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 124 GERMANY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 125 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 GERMANY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 128 FRANCE IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 FRANCE BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 130 FRANCE BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 131 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 132 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 133 FRANCE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 134 FRANCE CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 135 FRANCE NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 136 FRANCE PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 137 FRANCE CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 138 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 139 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 140 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 141 FRANCE INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 142 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 143 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 144 FRANCE PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 145 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 146 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 147 FRANCE KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 148 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 149 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 150 FRANCE SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 151 FRANCE DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 152 FRANCE PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 153 FRANCE RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 154 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 155 FRANCE KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 156 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 157 UNITED KINGDOM IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 158 UNITED KINGDOM BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 159 UNITED KINGDOM BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 160 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 161 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 162 UNITED KINGDOM RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 163 UNITED KINGDOM CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 164 UNITED KINGDOM NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 165 UNITED KINGDOM PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 166 UNITED KINGDOM CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 167 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 168 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 169 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 170 UNITED KINGDOM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 171 UNITED KINGDOM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 172 UNITED KINGDOM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 173 UNITED KINGDOM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 174 UNITED KINGDOM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 175 UNITED KINGDOM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 176 UNITED KINGDOM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 177 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 178 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 179 UNITED KINGDOM SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 180 UNITED KINGDOM DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 181 UNITED KINGDOM PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 182 UNITED KINGDOM RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 183 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 184 UNITED KINGDOM KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 185 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 186 ITALY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 187 ITALY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 188 ITALY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 189 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 190 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 191 ITALY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 ITALY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 193 ITALY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 194 ITALY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 195 ITALY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 196 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 ITALY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 198 ITALY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 199 ITALY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 200 ITALY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 201 ITALY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 202 ITALY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 203 ITALY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 204 ITALY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 205 ITALY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 206 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 207 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 208 ITALY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 209 ITALY DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 210 ITALY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 211 ITALY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 212 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 213 ITALY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 214 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 215 SPAIN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 216 SPAIN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 217 SPAIN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 218 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 219 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 220 SPAIN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 221 SPAIN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 222 SPAIN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 223 SPAIN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 224 SPAIN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 225 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 226 SPAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 227 SPAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 228 SPAIN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 229 SPAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 230 SPAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 231 SPAIN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 232 SPAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 233 SPAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 234 SPAIN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 235 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 236 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 237 SPAIN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 238 SPAIN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 SPAIN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 SPAIN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 SPAIN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 243 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 244 RUSSIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 245 RUSSIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 246 RUSSIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 247 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 248 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 249 RUSSIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 250 RUSSIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 251 RUSSIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 252 RUSSIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 253 RUSSIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 254 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 255 RUSSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 256 RUSSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 257 RUSSIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 258 RUSSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 259 RUSSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 260 RUSSIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 261 RUSSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 262 RUSSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 263 RUSSIA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 264 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 265 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 266 RUSSIA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 267 RUSSIA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 268 RUSSIA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 269 RUSSIA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 270 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 271 RUSSIA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 272 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 273 NETHERLANDS IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 274 NETHERLANDS BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 275 NETHERLANDS BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 276 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 277 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 278 NETHERLANDS RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 279 NETHERLANDS CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 280 NETHERLANDS NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 281 NETHERLANDS PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 282 NETHERLANDS CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 283 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 284 NETHERLANDS INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 285 NETHERLANDS INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 286 NETHERLANDS INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 287 NETHERLANDS PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 288 NETHERLANDS PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 289 NETHERLANDS PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 290 NETHERLANDS KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 291 NETHERLANDS KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 292 NETHERLANDS KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 293 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 294 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 295 NETHERLANDS SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 296 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 297 NETHERLANDS PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 298 NETHERLANDS RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 299 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 300 NETHERLANDS KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 301 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 302 POLAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 303 POLAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 304 POLAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 305 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 306 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 307 POLAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 308 POLAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 309 POLAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 310 POLAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 311 POLAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 312 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 313 POLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 314 POLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 315 POLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 316 POLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 317 POLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 318 POLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 319 POLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 320 POLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 321 POLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 322 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 323 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 324 POLAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 325 POLAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 326 POLAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 327 POLAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 328 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 329 POLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 330 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 331 SWITZERLAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 332 SWITZERLAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 333 SWITZERLAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 334 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 335 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 336 SWITZERLAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 337 SWITZERLAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 338 SWITZERLAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 339 SWITZERLAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 340 SWITZERLAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 341 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 342 SWITZERLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 343 SWITZERLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 344 SWITZERLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 345 SWITZERLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 346 SWITZERLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 347 SWITZERLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 348 SWITZERLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 349 SWITZERLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 350 SWITZERLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 351 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 352 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 353 SWITZERLAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 354 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 355 SWITZERLAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 356 SWITZERLAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 357 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 358 SWITZERLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 359 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 360 BELGIUM IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 361 BELGIUM BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 362 BELGIUM BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 363 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 364 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 365 BELGIUM RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 366 BELGIUM CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 367 BELGIUM NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 368 BELGIUM PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 369 BELGIUM CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 370 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 371 BELGIUM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 372 BELGIUM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 373 BELGIUM INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 374 BELGIUM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 375 BELGIUM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 376 BELGIUM PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 377 BELGIUM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 378 BELGIUM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 379 BELGIUM KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 380 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 381 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 382 BELGIUM SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 383 BELGIUM DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 384 BELGIUM PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 385 BELGIUM RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 386 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 387 BELGIUM KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 388 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 389 SWEDEN IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 390 SWEDEN BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 391 SWEDEN BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 392 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 393 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 394 SWEDEN RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION))
TABLE 395 SWEDEN CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 396 SWEDEN NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 397 SWEDEN PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 398 SWEDEN CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 399 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 400 SWEDEN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 401 SWEDEN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 402 SWEDEN INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 403 SWEDEN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 404 SWEDEN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 405 SWEDEN PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 406 SWEDEN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 407 SWEDEN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 408 SWEDEN KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 409 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 410 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 411 SWEDEN SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 412 SWEDEN DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 413 SWEDEN PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 414 SWEDEN RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 415 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 416 SWEDEN KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 417 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 418 NORWAY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 419 NORWAY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 420 NORWAY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 421 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 422 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 423 NORWAY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 424 NORWAY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 425 NORWAY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 426 NORWAY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 427 NORWAY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 428 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 429 NORWAY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 430 NORWAY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 431 NORWAY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 432 NORWAY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 433 NORWAY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 434 NORWAY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 435 NORWAY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 436 NORWAY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 437 NORWAY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 438 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 439 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 440 NORWAY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 441 NORWAY DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 442 NORWAY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 443 NORWAY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 444 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 445 NORWAY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 446 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 447 DENMARK IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 448 DENMARK BIOPSY TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 449 DENMARK BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 450 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 451 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 452 DENMARK RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 453 DENMARK CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 454 DENMARK NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 455 DENMARK PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 456 DENMARK CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 457 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 458 DENMARK INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 459 DENMARK INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 460 DENMARK INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 461 DENMARK PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 462 DENMARK PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 463 DENMARK PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 464 DENMARK KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 465 DENMARK KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 466 DENMARK KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 467 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 468 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 469 DENMARK SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 470 DENMARK DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 471 DENMARK PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 472 DENMARK RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 473 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 474 DENMARK KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 475 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 476 FINLAND IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 477 FINLAND BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 478 FINLAND BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 479 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 480 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 481 FINLAND RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 482 FINLAND CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 483 FINLAND NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 484 FINLAND PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 485 FINLAND CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 486 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 487 FINLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 488 FINLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 489 FINLAND INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 490 FINLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 491 FINLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 492 FINLAND PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 493 FINLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 494 FINLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 495 FINLAND KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 496 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 497 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 498 FINLAND SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 499 FINLAND DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 500 FINLAND PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 501 FINLAND RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 502 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 503 FINLAND KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 504 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 505 TURKEY IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 506 TURKEY BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 507 TURKEY BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 508 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 509 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 510 TURKEY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 511 TURKEY CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 512 TURKEY NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION)
TABLE 513 TURKEY PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 514 TURKEY CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 515 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 516 TURKEY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 517 TURKEY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 518 TURKEY INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 519 TURKEY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 520 TURKEY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 521 TURKEY PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 522 TURKEY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 523 TURKEY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS)
TABLE 524 TURKEY KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD)
TABLE 525 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 526 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 527 TURKEY SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 528 TURKEY DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 529 TURKEY PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 530 TURKEY RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 531 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 532 TURKEY KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 533 REST OF EUROPE KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE KIDNEY CANCER DIAGNOSTICS MARKET
FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020)
FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020)
FIGURE 16 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022
FIGURE 17 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 18 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030)
FIGURE 19 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE
FIGURE 20 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022
FIGURE 21 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 22 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030)
FIGURE 23 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE
FIGURE 24 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022
FIGURE 25 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION)
FIGURE 26 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030)
FIGURE 27 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE
FIGURE 28 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022
FIGURE 29 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 30 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030)
FIGURE 31 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE
FIGURE 32 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022
FIGURE 33 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 34 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 35 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE
FIGURE 36 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022
FIGURE 37 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 38 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030)
FIGURE 39 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE
FIGURE 40 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 41 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 42 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 43 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 44 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 45 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 46 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 47 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 49 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 50 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 51 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 52 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030)
FIGURE 53 EUROPE KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
